Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
NCT07466238Recruiting
- Sponsor
- Peking University
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label trial of bevacizumab, gemcitabine, oxaliplatin and fluorouracil in biliary tract cancer (BTC) (2 arms), sponsored by Peking University. Primary endpoints: Overall Survival at 36 months and Clinical Complete Response Rate at 36 months. Started Mar 2026; status: recruiting.
02
Drugs
bevacizumabgemcitabineoxaliplatinfluorouracil
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07466238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466238.